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Abstract Liver disease is a growing global health problem, as
deaths from end-stage liver cirrhosis and cancer are rising
across the world. At present, pharmacologic approaches to
effectively treat or prevent liver disease are extremely limited.
Hypoxia-inducible factor (HIF) is a transcription factor that
regulates diverse signaling pathways enabling adaptive cellu-
lar responses to perturbations of the tissue microenvironment.
HIF activation through hypoxia-dependent and hypoxia-
independent signals have been reported in liver disease of
diverse etiologies, from ischemia-reperfusion-induced acute
liver injury to chronic liver diseases caused by viral infection,
excessive alcohol consumption, or metabolic disorders. This
review summarizes the evidence for HIF stabilization in liver
disease, discusses the mechanistic involvement of HIFs in
disease development, and explores the potential of pharmaco-
logical HIF modifiers in the treatment of liver disease.
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Introduction
Acute and chronic liver diseases are a significant global public
health issue. Acute liver injury due to adverse drug reactions
accounts for more than half of the cases of acute liver failure
and 15 % of the patients undergoing liver transplantation.
Ischemia-reperfusion (IR) is another major cause of acute liver
injury, which represents a key challenge in liver transplanta-
tion and significantly contributes to postoperative morbidity
and mortality. Chronic liver diseases caused by viral infection,
alcohol abuse, or obesity-associated metabolic disorder can
develop into end-stage liver cirrhosis and liver cancer. It is
estimated that in 2013 alone, there were 792,000 new cases
of liver cancer and 818,000 deaths globally, with 86 % occur-
ring in developing countries and 14 % occurring in developed
countries [1].
Hypoxia-inducible factor (HIF) is a transcription factor reg-
ulating a wide range of genes involved in cellular responses to
hypoxia and other tissue environmental cues. HIF is a hetero-
dimeric complex consisting of a constitutively expressed β-
subunit and an oxygen-sensitive α-subunit. To date, three iso-
forms of HIF-α subunit have been described, in which HIF1α
and HIF2α are the best characterized. The α subunit is rapidly
degraded under normoxic conditions and stabilized during hyp-
oxia. The critical step in α-subunit degradation is the hydrox-
ylation of proline residues by prolyl hydroxylase domain en-
zymes (PHD1-3), allowing recognition of the α-subunit by the
von Hippel-Lindau (VHL) E3 ubiquitin ligase complex and
subsequent proteasomal degradation [2, 3]. During hypoxia,
PHD activity is limited by oxygen availability, leading to the
stabilization of HIF-α subunit and its nuclear translocation. The
α and β subunits heterodimerize and form a complex with
CREB-binding protein (CBP)/p300, thereby exerting their tran-
scriptional activity. A second hypoxic switch operates in the
carboxy terminal transactivation domain of HIF-α, where
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hypoxia blocks the hydroxylation of Asn803, thereby facilitat-
ing the recruitment of CBP/p300 [4].
Increased expression of HIF-1α and HIF-2α has been report-
ed in many liver diseases, including nonalcoholic fatty liver dis-
ease (NAFLD), alcoholic liver disease (ALD), IR-induced liver
injury, and hepatocellular carcinoma (HCC) [5–10]. A common
feature of these liver diseases is tissue hypoxia due to an imbal-
ance of metabolic demand and supply [11–14]. Oxygen con-
sumption by hepatocytes and infiltrating inflammatory leuko-
cytes is dramatically increased. For example, infiltrating neutro-
phils consume copious amounts of oxygen during oxidative
burst. [15] In the meantime, oxygen supply is reduced due to
vascular dysfunction, thrombosis, or fibrosis. Aside from hyp-
oxia, other conditions associated with liver disease can also sta-
bilize HIFs. For example, hepatic endotoxin levels are increased
in NAFLD and ALD, and lipopolysaccharide (LPS) has been
reported to stabilize HIF [16–18]. LPS-induced HIF activation is
dependent on toll-like receptor (TLR)-4 and mediated through
NF-κB and MAPK pathways [16, 17]. During inflammation, a
TCA cycle intermediate, succinate is increased, and it functions
as a HIF activator [19]. Reactive oxygen species (ROS) has also
been shown to stabilize HIFs [20], and increased production of
ROS is a common phenomenon in liver pathological conditions.
Furthermore, evidence suggests that hepatitis B and C viruses
directly stabilize HIFs under normoxic conditions (Fig. 1).
HIFs transcriptionally regulate a wide range of genes in-
volved in cell proliferation (e.g., transforming growth factor
(Tgfα) and insulin-like growth factor (Igf-2)), energy metabo-
lism (e.g., pyruvate dehydrogenase kinase (Pdk1) and glucose
transporter (Glut-1)), migration (e.g., zinc finger protein SNAI1
(Snail), twist family BHLH transcription factor (Twist1) and
matrix metalloproteinases (MMPs)), and angiogenesis (e.g., vas-
cular endothelial growth factor (Vegf) and platelet-derived
growth factor (Pdgf-b)). A common response to both acute and
chronic tissue injury is inflammation. HIF plays an important
role in regulating innate and adaptive immune cells and their
products involved in tissue inflammation. On the one hand, some
studies suggest that HIFs play an important functional role in
enabling innate to function in a hypoxic micro-environment. For
example, bacterial killing is critically regulated by HIF1A in
myeloid phagocytes [21]. Similarly, a recent study demonstrates
that lipopolysaccharide-induced succinate stabilizes HIF1A and
identifies succinate as a metabolite in innate immune signaling,
which enhances interleukin-1β production during inflammation
via HIF [19]. On the other hand, many transcriptional targets of
HIFs are anti-inflammatory, for example, the extracellular signal-
ing molecule adenosine. As such, gene-targeted mice for the
Adora2b adenosine receptor are more prone to inflammation
[22]. Also, many studies indicate that deletion of HIFs in models
of acute or chronic inflammation is involved in a negative feed-
back loop dampening innate or adaptive immune responses
[23–25]. As such, it is tempting to speculate that HIF could
potentially function to enhance bactericidal effects of innate
immune cells, while simultaneously functioning to prevent
immune-mediated collateral tissue damage. These findings
would indicate that HIF activators could be potent therapeutics
to dampen inappropriate liver inflammation, such as occurs in
the setting of ischemia and reperfusion injury [26–28].
Overall, the HIF-mediated adaptive responses to tissue hyp-
oxia and other micro-environmental changes are critical for tis-
sue recovery and repair from injury; and thus, HIF stabilization
confers hepato-protection during acute liver damage. However,
in chronic liver disease, prolonged HIF activation may be detri-
mental through accelerating fibrosis development, facilitating
viral replication, and promoting tumor cell growth and metasta-





















Fig. 1 Hypoxia-dependent and hypoxia-independent mechanisms
responsible for hepatic stabilization of hypoxia-inducible factor HIF.
Under normoxic conditions, HIF is hydroxylated via prolyl
hydroxylases (PHDs) and thereby target HIF for proteasomal
degradation. Hypoxia-dependent and hypoxia-independent pathways
can result in PHD inhibition and concomitant HIF stabilization during
liver disease. The left side of the figure displays conditions of liver disease
that directly lead to a hypoxic microenvironment. During conditions of
liver disease, imbalance in supply and demand for metabolites—
particularly oxygen—can lead to hepatic hypoxia, including diminished
supply with oxygen through the vasculature. Hypoxia-associated
increases in reactive oxygen species (ROS) have been reported to lead
to PHD inhibition. Similarly, infiltrating inflammatory cells can deplete
the microenvironment from oxygen, for example, poly-morphonuclear
neutrophils (PMN) undergoing PMN burst [15]. Hypoxia-independent
pathways leading to PHD inhibition include activation of toll-like
receptors (particularly TLR4) through bacterial products, such as
lipopolysaccharide (LPS). Accumulation of the citrate cycle
intermediate succinate can function as a PHD inhibitor [181]. Iron
depletion of the micro-environment for example through bacterial
siderophores can lead to PHD inhibition and HIF stabilization [182].
Moreover, elevated transcription of HIF can be a direct effect during
infection with hepatitis B (HBV) or hepatitis C (HCV) virus
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evidence for the involvement of HIFs in a variety of acute and
chronic liver diseases, (ii) discuss the current understanding and
knowledge gaps of the mechanistic involvement of HIF1α and
HIF2α in the disease development and progression (Table 1),
and (iii) highlight the potentials of activating or inhibiting HIFs
as therapeutic interventions to treat various liver diseases
(Table 2).
HIF in ischemia-reperfusion (IR)-induced acute liver
damage
IR is characterized as a restriction of blood supply to an organ
followed by reperfusion and re-oxygenation of blood vessels.
Restriction of blood supply causes tissue hypoxia and imbalance
of metabolic supply and demand [26]. Reperfusion is usually
accompanied by tissue damage and inflammatory responses.
IR liver injury occurs in a number of clinical settings such as
hemorrhagic shock, trauma, liver surgery, and liver transplanta-
tion [29], which is the only effective treatment for end-stage liver
diseases. Associated with causing liver dysfunction and even
liver failure, IR liver injury represents the major challenge of
liver transplantation and significantly contributes to postopera-
tive morbidity and mortality [30]. There are two types of IR liver
injury caused by warm IR and cold IR. The warm IR develops
during liver transplantation surgery, shock, or trauma. The cold
IR occurs during ex vivo organ preservation. The ischemia time
is a good predictor of patient and graft survival. During surgery,
the warm ischemic time ranging from 15 to 50 min will result in
significant morbidity [31]. A meta-analysis of 26 studies re-
vealed that both patient and graft survival declines significant
when the cold-ischemia time exceeds 12.5 h [32]. It has also
been reported that cold-ischemia time longer than 6 h results in
nearly threefold higher risk of graft failure [33]. Due to organ
shortage, currently only one third of the patients waiting for a
liver transplant actually undergo the procedure (US Department
of Health and Human Services. Organ Procurement and
Transplantation Network (online), http://optn.transplant.hrsa.
gov/data/ (2012). To cope with this issue, criteria for donor
organs have been extended to include those from older,
steatotic, and non-heart-beating donors. These “marginal” organs
will be more prone to damage during procurement, preservation,
and surgery and thus are particularly susceptible to IR injury.
Complex molecular and cellular mechanisms account for
IR liver injury. Microcirculation dysfunction occurs at early
time points as result of vasoconstriction and the swelling of
sinusoidal endothelial cell and Kupffer cell. The narrowing of
sinusoids entraps leukocytes, further hindering blood flow and
causing tissue hypoxia. In such settings, the “master regula-
tor” of cellular response to hypoxia, HIF, is stabilized. The
HIF activation is likely an adaptive response to IR. Studies
using pharmacological approaches to stabilize HIFs have re-
vealed their protective function during IR liver injury [34–36].
The underlying mechanism of the protection involves HIF-
induced transcriptional regulation of myriad of genes that reg-
ulate multiple pathways of cell adaptive responses to hypoxia,
including reprogramming of cellular energymetabolism (Pdk-
1, Glut-1, carbonic anhydrase (CA4/9)) and promoting angio-
genesis ((Vegf, nitric oxide synthase (NOS)). Moreover, HIFs
play an important role in the upregulation of cytoprotective
molecules, such as heme oxygenase (Hmox-1), heat-shock
proteins (HSPs), and erythropoietin. It has been reported that
HIF-1α suppresses hepatocellular carcinoma cell apoptosis
through upregulating Bcl-2 and inhibiting the expression and
mitochondrial release of Omi/HtrA2, a serine protease in-
volved in capase-dependent apoptosis [37]. It has also been
demonstrated that HIF-1α can reduce palmitic acid-induced
lipotoxicity and ER stress in hepatocytes [38]. These findings
suggest that the role of HIF in promoting hepatocyte survival
may be an important protective mechanism during I/R liver
injury.
It has been reported that prolyl hydroxylase-1 (PHD1) neg-
atively regulates IkappaB kinase-beta and thus NF-κB activity
[39], suggesting that inhibiting PHD1 could promote cell sur-
vival through enhancing NF-κB activation. In fact, it has been
shown that PHD1−/− mice are less susceptible to the develop-
ment of colitis due to decreased epithelial cell apoptosis and
enhanced epithelial barrier function [40]. There have been two
studies of the role of PHD1 in liver injury, and the findings are
consistent with the notion that PHD1 inhibition promotes cell
survival. One study demonstrated that PHD1−/− mice were
Table 1 Comparing the roles of
HIF1α and HIF2α in various
liver diseases
Liver disease Role of HIF1α Role of HIF2α
I/R liver injury Protective [34, 35, 41] Protective [46]
NAFLD Not clear Contributes to steatosis [13, 77, 78]
ALD Controversial [92, 93] Not been studied
Liver fibrosis/cirrhosis Pro-fibrogenic [102, 104, 105] Not been studied
Viral hepatitis Contributes to disease progression
[14, 115, 121]
Contributes to disease progression [122, 123]
HCC Contributes to tumorigenesis
[143, 144, 154, 159]
Controversial [133, 146, 147]
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protected against acute I/R liver injury [41]. Moreover, knock-
down of PHD1 in hepatocytes conferred tolerance of the cells
to hypoxia due to reduced oxidative stress. Another study
demonstrated that liver regeneration was significantly en-
hanced in PHD1−/− mice compared to WT mice. This effect
was due to increased hepatocyte proliferation with increases in
c-myc transcriptional activity [42]. The results from both stud-
ies suggest that short-term PHD1 inhibition may be a novel
therapy to attenuate or prevent I/R liver injury and to facilitate
liver regeneration after surgical resection.
Furthermore, hypoxia-driven increases in extracellular
adenosine signaling represent an important pathway mediat-
ing the protective effect of HIFs during IR liver injury. In the
extracellular compart, adenosine can function as a signaling
molecule. It mainly stems from the breakdown of extracellular
nucleotides and nucleosides, such as ATP, ADP, or AMP [43,
44]. Several studies have shown that during conditions of
ischemia and reperfusion injury, the enzymatic system that
controls extracellular nucleotide generation is transcriptional-
ly induced, including the enzymes CD39 (ATP/ADP conver-
sion to AMP) and CD73 (AMP conversion to adenosine)
[45–47]. While CD39 is transcriptionally controlled by the
transcription factor SP1, CD73 is a direct HIF target gene
(Fig. 2). Moreover, other studies demonstrate that adenosine
receptor signaling is increased during conditions of limited
oxygen availability due to HIF-dependent induction of the
A2A and A2B adenosine receptors [48, 49]. Such liver pro-
tective pathways can for instances be harnessed by hypoxic
preconditioning, leading to a concomitant induction of the
Adora2b adenosine receptor subtype [50], a known transcrip-
tional target of HIF1α [51, 52]. Other studies implicate the
Adora2a adenosine receptor in liver protection [53], which is a
known target gene of HIF2α [54]. Again, other studies impli-
cate HIF-controlled transcriptional repression of adenosine
transporters in hypoxia-elicited adaptation and tissue protec-
tion [55, 56]. As such, many studies provide a rational for
hypoxia-elicited increases in adenosine generation and signal-
ing as an important endpoint in liver protection during ische-
mia and reperfusion injury (Fig. 2).
Overall, pre-clinical studies have provided strong evidence
highlighting the therapeutic potential of HIF stabilization in
attenuation and prevention of IR liver injury. One approach is
surgical preconditioning by clamping the hepatic artery, which
has been shown to sufficiently activate HIF signaling pathway
and promote cell survival [57, 58]. A clinical trial of ischemic
preconditioning induced by 10-min hiliar clamping demon-
strated improved biochemical markers of liver function and
increased HIF-1α levels [59]. However, ischemic precondi-
tioning in a surgical transplant setting is more challenging than
pharmacological activation of HIFs. As such, pre-clinical and
clinical studies are on-going to explore the efficacy of HIF
modifiers. Iron chelator, mangafodipir, which inhibits PHDs,
has been shown to activate HIF-1α and mitigate IR liver injury
in rats [34]. A PHD inhibitor, ethyl 3,4-dihyroxybenzoate, has
been shown to activate HIF-1α and its target Hmox-1, thereby
inhibiting mitochondrial permeability transition and attenuat-
ing IR liver injury [36]. More recently, several promising phar-
macologic HIF activators are being studied in patients for the
treatment of renal anemia [60]. Similar studies evaluating the
beneficial effects of HIF stabilization before or during liver
transplantation are urgently needed. The use of pharmacologi-
cal HIF activators could represent a novel therapeutic approach
to significantly dampen hepatic ischemia and reperfusion inju-
ry and thereby contributing to improved outcomes during liver
Table 2 Examples of ongoing clinical trials related to HIF and liver diseases
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transplantation. Similarly, clinical studies exploring adenosine
signaling in the context of hepato-protection during liver trans-
plantation have to be further explored.
HIF and nonalcoholic fatty liver disease (NAFLD)
NAFLD is becoming the most common chronic liver disease
worldwide due to the epidemic increase of incidence of obe-
sity, diabetes and metabolic diseases. It is estimated that
NAFLD affects 9–37 % of the population worldwide
[61–63]. In the US, NAFLD affects 30 % of the general pop-
ulation and about 90 % of the morbidly obese individuals [64,
65]. NAFLD consists a range of disorders from simple fat
accumulation in the liver (steatosis) to pathological nonalco-
holic steatohepatitis. Steatosis is defined as deposition of tri-
glycerides exceeding 55 mg per gram of liver or the presence
of triglycerides droplets in more than 5 % of hepatocytes [66].
Hepatic triglycerides formation is attributable to three
pathways, including diet, de novo lipogenesis, and fatty acid
release from the adipose tissues. In the liver, free fatty acid is
removed by oxidation in the mitochondria, stored as triglyc-
erides lipid droplets or secreted as a constituent of very-low-
density lipoproteins (VLDL). Steatosis arises from an imbal-
anced hepatic triglycerides acquisition and removal. For ex-
ample, it is estimated that a typical American daily diet
consisting 100 g of fat will result in 20 g of fat deposition in
the liver, accounting for half of the total triglycerides content
of an average liver. Although steatosis is benign initially, it
represents a key step in the development of hepatitis with
hepatocyte damage, infiltration of inflammatory leukocytes,
and collagen deposition (fibrosis). In approximately 10–
30 % of individuals with nonalcoholic steatohepatitis, the dis-
ease progresses into liver cirrhosis within 10 years [67].
Among liver cirrhosis patients, as high as 40–60 % will de-
velop hepatocellular carcinoma (HCC) [68, 69].
Hypoxia occurs in the development and progression of
NAFLD as result of increased metabolic demands and
oxygen consumption, as well as hepatic sinusoids con-
striction due to hepatocyte swelling and fibrotic scar ac-
cumulation [70–72]. Hypoxia has been associated with
perturbation of lipid homeostasis. Hypoxic stress of cells
or tissues results in lipid accumulation [73, 74]. It is also
reported that hypoxia induces genes involved in lipid syn-
thesis, storage, and uptake [75, 76]. These findings, as
well as the observation of HIF stabilization in animals
and patients with NAFLD, implicate a role for HIF in
regulating hepatic lipid metabolism. The majority of the
published reports support the hypothesis that HIFs, HIF-
2α in particular, promote hepatic steatosis.
It has been reported that deletion of both PHD2 and PHD3
in the liver results in severe hepatic steatosis with increased
expression of HIFs [77]. Mice with hepatocyte-specific dele-
tion of VHL, resulting in the overexpression of both HIF-1α
and HIF-2α, also exhibit increased hepatic lipid accumulate
compared with WT mice [78]. Similar to the VHL knockout
mice, hepatic steatosis is also observed in another mouse mod-
el of HIF overexpression, in which HIF-1α and HIF-2α var-
iants that cannot be hydroxylated were introduced [79].
Between the two isoforms, HIF-2α is shown to play a more
important role in regulating hepatic lipid metabolism. In the
PHD2/PHD3 double knockout mice, it is demonstrated that
HIF-2α, but not HIF-1α, is associated with steatosis [77].
Similarly, in the VHL-deficient mice, deletion of HIF-2α,
but not HIF-1α, attenuates hepatic steatosis, suggesting that
HIF-2α is the main promoter of steatosis [13, 78]. Although
the direct molecular targets of HIF-2α are not clear, the data
demonstrate that HIF-2α-overexpressed mice exhibit in-
creased expression of lipogenic genes (SREBP1c and FAS)
and decreased expression of genes involved in fatty acid ox-
















Fig. 2 Hypoxia-stimulated adenosine production and signaling during
hepatic ischemia and reperfusion injury. During liver transplantation,
ischemia and reperfusion injury of the liver graft results in profound
hypoxia and concomitant increases in hypoxia-dependent signaling
pathways. One of the main outcomes of these transcriptional programs
is increased production and signaling of the extracellular signaling
molecule adenosine. During liver injury, multiple cell types release
nucleotides in the form of adenosine triphosphate (ATP) or adenosine
diphosphate (ADP). ATP and ADP are enzymatically converted via
CD39 to adenosine monophosphate (AMP), which in turn is converted
to adenosine via the enzyme CD73 [49]. Conditions of hepatic hypoxia
will result in the transcriptional induction of CD39 via the transcription
factor SP1 [45] and of CD73 via the transcription factor hypoxia-
inducible factor HIF [47]. Similarly, the A2A and A2B adenosine
receptors are transcriptionally induced by HIF [48, 49]. Many studies
have implicated increased extracellular adenosine signaling in liver
protection from ischemia and reperfusion injury [53]
J Mol Med (2016) 94:613–627 617
Accumulating evidence suggests an important role of HIFs
in the regulation of lipid metabolism and NAFLD develop-
ment [80]. However, it remains unclear whether genes in-
volved in lipogenesis, lipid storage, and fatty acid oxidation
are direct transcriptional targets of HIF2α (or HIF-1α) or they
are increased as an indirect effect of HIF stabilization. More
detailed molecular studies to address this question are warrant-
ed to elucidate the mechanism of HIF-mediated regulation of
lipid metabolism. The knowledge gained from such studies
will substantiate the involvement of HIFs in the pathogenesis
of NAFLD and provide the basis for developing HIF-targeted
therapeutic strategies.
HIF and alcoholic liver disease (ALD)
Alcohol abuse is a leading cause of chronic liver disease that
affects millions of people worldwide. ALD encompasses a
range of disorders from steatosis to alcoholic hepatitis, cirrho-
sis, and HCC. Alcohol-related liver cirrhosis accounts for
nearly half of liver cirrhosis-associated deaths in the US [81,
82]. Among patients with alcohol-induced advanced liver cir-
rhosis, approximately 10 % will develop HCC [83]. Although
the majority of heavy drinkers (>90%) develop steatosis, only
about one third will develop cirrhosis, suggesting the involve-
ment of other risk factors. For example, females are more
susceptible to ALD than males, probably due to estrogen,
higher proportion of body fat, and lower levels of alcoholic
dehydrogenase. As another risk factor, obesity accelerates cir-
rhosis development in ALD patients [84, 85]. Moreover, it is
clearly shown that hepatitis B or C and alcohol drinking syn-
ergistically accelerate the disease progression to liver cirrhosis
and HCC [86]. Aside from the direct hepatotoxic effect of
ethanol metabolism, various hepatic non-parenchymal cells
and their soluble products contribute to liver injury and in-
flammation during ALD. A better understanding of the path-
ogenesis is important for developing new therapies, which
currently are limited to abstinence and corticosteroids.
After either acute or chronic ethanol, oxygen consumption
by the liver is increased [87, 88] due to ethanol-induced hor-
mones (e.g., catecholamine), metabolic demands, and oxidative
stress [89]. The resulting liver tissue hypoxia is observed in
animal models and in patients with ALD [89–91]. HIF stabili-
zation has been reported in chronic alcoholics and in a murine
model of ALD [92–94]. Alcohol-induced fatty liver shares
similar clinical features and underlying pathogenesis with
NAFLD. Therefore, it is likely that HIF-2α contributes to the
development of hepatic steatosis during ALD as in NAFLD.
However, the role of HIF-2α in the pathogenesis of ALD has
not been investigated. Up to date, there are only two reports
describing the involvement of HIF-1α in alcohol-associated
hepatic steatosis, and their findings are contradictory.
Both studies used the HIF-1α f/f/AlbCre mouse, in which
HIF-1α is deleted conditionally in hepatocytes. The earlier
study demonstrated that compared with WT mice, those de-
ficient of HIF-1α developed reduced hepatic steatosis and
hypertriglyceridemia [93]. Although the signaling pathway
that mediates the downstream pro-steatotic function of HIF-
1α was not a focus, this study demonstrated that monocyte
chemotactic protein (MCP)-1 was an upstream activator that
increased HIF-1α protein expression and its DNA-binding
activity. In contrast, the later study demonstrated that alcohol
feeding led to enhanced hepatic steatosis and serum triglyc-
erides when HIF-1α was deleted in hepatocytes [92]. The
data showed that lipogenic genes, such as acyl-CoA carbox-
ylase (ACC)-1, fatty acid synthase (FAS), and stearoyl-CoA
desaturase (SCD)-1 were expressed at higher levels in HIF-
1α-deficient than WT mice. These lipogenic genes are reg-
ulated by sterol regulatory element-binding protein
(SREBP)-1c, which is repressed by differentiated embryo
chondrocyte 1 (DEC1). DEC1 is known to be a transcrip-
tional target of HIF-1α. In supporting the role of DEC1 in
mediating the anti-steatotic function of HIF-1α, the data
demonstrated that DEC1 was elevated in alcohol-fed WT
but not HIF-1α-deficient mice. Furthermore, DEC1-
expressing plasmid, as well as the PHD inhibitor
dimethyloxaloylglycine (DMOG), was able to ameliorate
steatosis in HIF-1α-deficient mice [92].
The discordant results obtained from the two studies may
be due to differences in the experimental details, such as the
dose of ethanol, gut microbiome differences of animals, and
the choice of control mice. Additional studies are warranted to
reconcile the discrepancies and more importantly, to elucidate
the molecular signaling pathways that mediate the involve-
ment of HIFs. Furthermore, these two reported studies only
focused on investigating the role of HIFs in alcohol-induced
steatosis, which is an early manifestation of ALD. However,
the disease progresses to much more severe forms including
steatohepatitis, cirrhosis, and HCC. It is important for future
studies to elucidate whether and how HIFs may play a role in
the disease progression.
HIF and liver fibrosis/cirrhosis
Chronic liver injury and inflammation caused by viral hepati-
tis B or C infections, alcohol abuse, NAFLD, and biliary ob-
struction often results in tissue fibrosis [95]. Fibrosis is part of
a normal wound-healing response to tissue injury. However,
repeated injury causes chronic inflammation, matrix deposi-
tion, and angiogenesis, which leads to progressive fibrosis. In
some patients, liver fibrosis progresses to cirrhosis, in which
hepatocytes are replaced by scar tissue with excess collagen
produced by hepatic stellate cells. Advanced liver cirrhosis is
characterized by portal hypertension and disruption of hepatic
architecture, which often result in liver failure requiring liver
transplantation [95]. As an end-stage liver disease, cirrhosis is
ranked as the tenth leading cause of death in the Western
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world [96]. It is estimated that a 10-year mortality rate of
established cirrhosis is 34–66 % [97]. Moreover, liver cirrho-
sis is clearly a risk factor for the development of HCC [98, 99].
Liver fibrosis causes an increased resistance to blood flow
[100], which together with sinusoidal capillarization and sinu-
soidal obstruction syndrome causes tissue hypoxia [101].
Interestingly, hypoxic areas co-localize with those of fibrosis,
suggesting a link between hypoxia and fibrogenesis [6].
Moreover, HIF stabilization has been reported in experimental
models of liver fibrosis [102]. These observations suggest that
HIFs may contribute to fibrosis development. In support of
this hypothesis, clinical studies of human cirrhotic liver reveal
that HMOX-1 and VEGF, well-known targets of HIFs, are
detected in cells of fibrotic septa [6, 10, 103].
Although the role of HIF-2α has not been investigated, the
pro-fibrogenenic effects of HIF-1α in multiple cell types of the
liver have been reported in experimental models. CCl4-induced
fibrosis is a commonly used model, in which mice are treated
with CCl4 twice weekly for at least 5 weeks. In this model, liver
fibrosis develops as result of chronic tissue damage and wound
healing. Surgical ligation of the bile duct represents another
commonly used model to induce obstructive cholestatic liver
injury, which causes inflammation and leads to liver fibrosis
after 21 days. It has been demonstrated that compared withWT
mice, those with hepatocyte-specific HIF-1α deletion devel-
oped reduced liver fibrosis when subjected to bile duct ligation
or chronic CCl4 treatment [102, 104]. Myeloid cell-specific
deletion of HIF-1α or HIF-1β suppresses bile duct ligation-
induced hepatic expression of Pdgf-b, alpha-smooth muscle
actin, and type I collagen, all markers of fibrosis [105].
Hypoxic exposure of hepatic stellate cells isolated from WT
and HIF-1α-deficient mice revealed that the expression of sev-
eral pro-fibrogenic factors, such as Vegf, placenta growth fac-
tor, macrophage migration inhibition factor, CCR1, and CCR5,
are dependent on HIF-1α [105].
HIF-induced fibrogenesis can be a direct or indirect effect of
HIF transcriptional activity.Many pro-fibrogenic factors, such as
Vegf, Mcp-1, plasminogen activator inhibitor-1, Pdgf-a, Pdgf-b,
fibroblast growth factor (Fgf)-2, and MMPs are transcriptional
targets of HIFs. Moreover, adenosine production and its receptor
signaling are regulated by HIFs, and adenosine signaling plays a
role in promoting liver fibrosis. It has been shown that activation
of Adora2A induces collagen production by hepatic stellate cells
[105], and inhibition or deletion of Adora2A suppresses liver
fibrogenesis [106, 107]. The pro-fibrotic function of adenosine
is also dependent on Adora2B, as its antagonist (MRS1754) has
been shown to reduce liver fibrosis [108].
Accumulating evidence now suggests a tight link between
angiogenesis and fibrogenesis, both occur during chronic in-
flammatory liver diseases. Many factors that are upregulated
during angiogenesis also have profibrogenic effects, such as
Vegf, Fgf2, and Pdgf. Therefore, the role of HIFs in promoting
angiogenesis may indirectly promote liver fibrosis. Another
indirect mechanism for the pro-fibrotic function of HIFs lies
in their role in promoting inflammatory leukocytes accumula-
tion in the liver. Infiltration of inflammatory cells require the
interaction between CXCR4 and its ligand, stromal cell-derived
factor-1 (SDF-1), both are HIF target genes [109]. In other
tissues, it has been demonstrated that HIF-1-dependent
epithelial-mesenchymal transition (EMT) contributes to
fibrogenesis. The mechanism involves HIF-induced upregula-
tion of lysyl oxidases, Snail1, and Twist expression [110, 111].
Therapy for fibrosis/cirrhosis is limited. Because of the
pro-fibrotic role HIFs, therapeutic inhibition of HIF-1α and/
or HIF-2α may attenuate fibrosis and slow its progression to
cirrhosis and HCC. However, HIF stabilization could also
improve ischemic disorders associated with cirrhosis. As
such, PHD inhibitors have been proposed for the treatment
of fibrosis. A recent study suggests that different HIF target
genes respond differently to PHD inhibitors [77]. Thus, it is
possible to design PHD inhibitors that induce erythropoietin
without significantly upregulating pro-fibrotic genes. To
achieve this, a better understanding of the target genes that
mediate the pro-fibrotic effect of HIFs is necessary.
HIF and viral hepatitis
Hepatitis B virus (HBV) is a member of the hepadnavirus
family. HBV infection affects 350–400 million people, ac-
counting for 5 % of the world population [112]. The majority
of infected people are Asian (75 %), whereas the prevalence is
low in Western countries (<1 %) [113]. Hepatitis C virus
(HCV) is a single-stranded RNA virus that infects and repli-
cates in hepatocytes. HCVinfection affects 180 million people
worldwide with higher prevalence in Japan, Europe, and the
US than other regions [112]. As a major cause of acute and
chronic liver injury, viral hepatitis often leads to serious end-
stage liver diseases such as cirrhosis and HCC [114]. Chronic
HBV infection has been shown to increase the risk of HCC
development by 5- to 100-fold. Similarly, HCV infection is
associated with 15- or 20-fold increase in the risk for devel-
oping HCC. In fact, more than 80 % of HCC patients has
HBVor HCV infection [113]. Although vaccination prevents
new cases, eradication of HBV in infected individuals has not
been effective. Recently developed HCV protease inhibitors
can efficiently eliminate the virus in the vast majority of pa-
tients. However, patients with hepatitis-associated cirrhosis
remain at high risk of developing HCC. Liver transplantation
is usually required once HCC occurs; however, with a high
cancer recurrent rate, “re-transplantation” is necessary.
Therefore, it remains important to identify new therapeutic
targets in order to develop strategies to ameliorate liver injury
caused by viral hepatitis and slow down the disease
progression.
HIF-1α and HIF-2α stabilization has been observed in
HBV- or HCV-infected cells and in liver biopsies from
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patients with chronic viral hepatitis [7, 9, 115]. Moreover,
HIF-1α polymorphisms are significantly associated with the
development of HBV-related HCC [116]. These observations
suggest a role for HIFs in the pathogenesis of viral hepatitis
and/or its progression to liver cirrhosis and HCC.
Numerous studies have demonstrated that HBV and HCV
can promote HIF protein stability and transcriptional activity
under normoxia. The hepatitis B viral X protein (HBx), which
is indispensable for viral replication, can directly interact with
the bHLH/PAS domain of HIFα subunit, thereby decreasing its
binding with pVHL and preventing degradation [117]. The
carboxy terminus of HBx was found to be critical in activating
HIFs [118]. Aside from directly stabilizing HIFs, HBx induces
HDAC1 and metastasis-associated protein 1, which inhibit
HIF-1α association with PHDs and thus stabilize HIFs [119].
Moreover, HBx is reported to activate MAPK pathway and in
turn activate HIF-1α [120]. HCV-induced HIF stabilization is
mainly due to HCV-induced oxidative stress and calcium sig-
naling, which cause the activation of NF-κB and STAT3 [12].
Evidence suggests that HIFs may directly promote viral rep-
lication. It has been reported that HCVreplication is augmented
under hypoxia, and that inhibition of HIF-1α suppresses viral
replication [14, 121]. HIFs may promote viral transmission and
replication in hepatocytes through modifying cell permeability
and energy metabolism. It is reported that HIF-induced VEGF
production depolarizes hepatocytes and facilitates viral entry
[122, 123]. HIF stabilization enhances cell survival, which in-
directly promotes viral infection. HCV is known to impair mi-
tochondrial oxidative phosphorylation; however, survival of
infected cells is preserved by increased glycolysis, an adaptive
response mediated by HIF-1α [115]. It is also reported that
HIF-1α stabilization modulates tight junction proteins and pro-
motes migration of HCV-infected cells [14].
Although some experimental data support a role for HIFs in
viral replication and cellular responses to viral infection, the tran-
scriptional targets involved remain to be elucidated. Aside from a
role in viral hepatitis, HIFs are likely involved in the disease
progression. HBx is strongly implicated in promoting angiogen-
esis, which is critical in fibrosis and cancer development. This
effect of HBx is mediated by its induction of HIF stabilization
and transcriptional activation of angiogenic factors such as
VEGF [9]. Moreover, HIF-induced adenosine production and
its signaling may impede host anti-viral immune responses, ow-
ing to the anti-inflammatory and immunosuppressive effects of
adenosine [124, 125]. These observations suggest that HIF may
serve as an important therapeutic target to inhibit viral replication,
boosting anti-viral immunity, and curbing the progression of viral
hepatitis to more severe forms of liver disease.
HIF and hepatocellular carcinoma (HCC)
HCC is one of the most common cancers withmore than half a
million new cases occurring worldwide each year. Because of
its poor prognosis and lack of treatment options, HCC ranks as
the fifth most common cause of death in men and the ninth in
women [126]. The majority of the HCC cases (>80 %) are
associated with chronic hepatitis B and C infection occurring
in less developed countries of East Asia and sub-Saharan
Africa [127, 128]. However, in the past 20 years, the incidence
of HCC in developed countries has been increasing. For ex-
ample, the annual incidence in the US has increased about
80 % in recent years [129]. HCC arises from liver cirrhosis,
which is progressed from chronic liver diseases, including
NAFLD, ALD, and viral hepatitis. Clinical observations re-
veal that liver cirrhosis is present in nearly 80 % of patients
with HCC, representing the most important risk factor for
HCC development [98, 99]. Current treatment options for
HCC are very limited. A small number of patients (15 %) with
early stage of the disease may be cured by liver resection or
transplantation. However, in about half of the patients, tumor
recurrence and metastases occur post-resection [130, 131].
The majority of the patients present with advanced HCC,
and it is refractory to chemotherapy. A multikinase inhibitor,
sorafenib, is currently the only first-line chemotherapy that
has been shown to improve overall survival for approximately
3 months. Therefore, it is important to better understand the
pathogenesis of HCC in order to develop novel therapeutic
strategies.
Both HIF-1α and HIF-2α have been observed to be
expressed at higher levels in HCC tissues than those in
matched, non-tumor-surrounding tissues [5, 8, 132]. The high
expression levels of HIF-1α or HIF-2α have been correlated
with worse tumor grade, venous invasion, intrahepatic metas-
tasis, and capsule infiltration [8, 133, 134]. HIF-1α and/or
HIF-2α stabilization is a poor prognostic marker, as it is asso-
ciated with shorter disease free period and lower overall sur-
vival rate [135–137]. Furthermore, genetic variations of HIF-
1α have been associated with higher risk of development and
prognosis of HCC and could serve as biomarkers [138, 139].
These clinical observations strongly suggest a pathological
role of HIFs in HCC development and progression.
Multiple factors contribute to the stabilization of HIFs dur-
ing HCC development. HCC typically arises in the condition
of cirrhosis with reduced vascularization, which leads to hyp-
oxia and HIF stabilization [140]. HIFs can also be activated by
HBVand HCV, which are major causes of HCC. In support of
this, in the majority of tumor specimens from HBV-related
HCC patients, increased expression of HIF-1α was observed
and the level correlates with the expression of HBx [141]. The
mechanistic involvement of HIFs in HCC development stems
from their gene transcriptional activities. Many HIF target
genes play critical role in the key processes of tumorigenesis,
such as cell proliferation, glucose metabolism, angiogenesis,
invasion, and metastasis [142, 143]. HIF-1α induces growth
factors, including TGFα and IGF-2, which promote cell pro-
liferation and survival [144]. HIF-1α directly binds to the
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promoter of Forkhead boxM1 (FoxM1), a transcription factor
that promotes proliferation in HCC [145]. The role of HIF-2α
in HCC is less clear, and there have been conflicting reports.
Some studies show that HIF-2α expression correlates with the
progression of HCC [133]. However, recent evidence also
supports a possible tumor suppressor role for HIF-2α in
HCC [146, 147].
Metabolic re-progamming from oxidative phosphorylation
to aerobic glycolysis, termed the Warburg effect, is a common
characteristic and survival mechanism of cancer cells. Key
enzymes that contribute to the Warburg effect, such as
PDK1 and lactate dehydrogenase A (LDHA), and the en-
zymes catalyzing glucose metabolism, such as phosphoglyc-
erate kinase 1 (PGK1), hexokinase 1 and 2 (HK1/2),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), phos-
phofructokinase (PFK), and the glucose transporters (GLUT-1
and GLUT-3), are all HIF-1α target genes [148–152].
Angiogenesis is critical for tumor growth. HIF-1α and HIF-
2α transcriptionally activate VEGF, which is a potent angio-
genic factor promoting endothelial cell proliferation, migra-
tion, and tube formation, especially in areas of hypoxia [153].
Aside from VEGF, HIF-1α also induces SDF-1, angiopoietin
2, placental growth factor, PDGF-B, and stem cell factor, all of
which have proangiogenic activities [154, 155].
Tumor metastasis is the primary factor of poor prognosis in
HCC. EMT is a critical step for tumor cells to acquire motility.
HIF-1α and HIF-2α play important roles in EMT through
downregulation of E-cadherin [132]. HIFs induce several
genes that are E-cadherin repressors, such as Snail, Twist1,
transcription factor 3 (TCF3), Zfhx1a, and Zfhx1b [132,
156–159]. In HBV- or HCV-positive HCC samples, a corre-
lation between Snail and Twist induction and tumor metastasis
has been established [160]. Moreover, HCV glycoproteins
induce cancer cell migration via upregulation of Snail and
Twist in an HIF-1α -dependent mechanism [14] .
Extracellular matrix degradation by MMPs, such as MMP2
and MMP9, is another key mechanism in tumor metastasis
[161, 162]. HIF-1α is an important transcription factor in up-
regulating the expression of MMPs [161, 163, 164]. It has
been reported that HIF-1 silencing by siRNA reduces
MMP2 and MMP9, thereby inhibiting migration and invasion
of malignant gliomas [165]. However, there is also evidence
supporting that HIF stabilization may improve tumor vessel
functions and reduce the risk of metastasis. For example, in
mice with haplodeficiency of PHD2, in which HIF-2α is in-
creased, the leakiness and distorted architecture of tumor ves-
sels are improved [48]. The “normalized” vasculature is asso-
ciated with reduced tumor invasiveness [48].
In summary, HIF stabilization and pathological contribu-
tion to HCC tumorigenesis have been demonstrated by nu-
merous studies. The current evidence highlights the poten-
tial of inhibiting HIF as a therapeutic approach to treat
HCC. Targeting HIF can be achieved by anti-sense
oligonucleotides or small molecule inhibitors that promote
HIF degradation or blocking HIF transcriptional activities.
These strategies are currently being explored in both pre-
clinical and clinical studies [166–169].
HIF modifiers as therapies to treat liver diseases
HIF has emerged as an important player in various liver dis-
eases. Evidence supports a hepato-protective function of HIFs
in acute liver injury, but a pathological role of HIFs in chronic
liver disease. Although it appears to be paradoxical, the oppo-
site involvement of HIFs in acute versus chronic liver diseases
is consistent with their transcriptional activities. The target
genes regulated by HIFs mediate adaptive responses to tissue
stress and damage; however, the same genes that promote cell
survival and proliferation and tissue repair lead to detrimental
effects in chronic situations. Therefore, targeting HIF for ther-
apies require very different approaches (Fig. 3). In situations
of acute liver damage, such as IR liver injury, drug-induced
liver failure, and acute hepatitis, HIF stabilization is desirable.
























Fig. 3 Targeting hepatic hypoxia-signaling for the treatment of liver
disease. Most evidence points towards a tissue protective role of
hypoxia-inducible transcription factors (HIFs) during acute liver injury,
while in conditions of chronic liver disease, inhibition of HIFs may be
desirable. Pharmacologic approaches to enhance hepatic stabilization of
HIFs during liver disease can be achieved by pharmacologic inhibitors of
prolyl hydroxylases (PHDs). Such compounds are currently examined in
clinical trials and could potentially provide liver protection during acute
liver injury. Clinical trials providing direct evidence for this hypothesis
have yet to be completed and published. During conditions of chronic
liver disease, inhibition of HIF stabilization in the liver may provide a
therapeutic benefit. For example, oligo-nucleotide inhibitors for HIF are
in clinical trials for the treatment of liver cancer
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currently being explored as treatment for ischemia, acute kid-
ney, lung, or heart injuries. For example, clinical trials are on-
going to evaluate the safety and efficacy of several PHD inhib-
itors, such as FG-4592, AKB-6548, GSK-1278863, in the treat-
ment of anemia in patients with chronic kidney disease, cardiac
ischemia, and those requiring dialysis [60]. These inhibitors
may be beneficial in attenuating acute liver injury. For example,
to prevent IR injury, HIF activators may be administered to
liver donors prior to explantation of the liver or added into the
perfusate of the explanted liver. Moreover, it has been reported
that HIF is stabilized and contributes to liver regeneration
through facilitating gluconeogenesis and promoting liver pro-
genitor cell proliferation [170–172]. Thus, a beneficial effect of
HIF stabilizers on major liver resection warrants investigation.
During phase II clinical trial of a PHD inhibitor, FG-2216,
hepatotoxicity was identified and determined to be an off-
target effect. A second-generation PHD inhibitor from
FibroGen, FG-4592 was found to be safe during phase II and
III clinical trials, and hepatotoxicity has not been reported for
other PHD inhibitors in clinical trials. Moreover, based on the
mechanism of action of the hydroxylase inhibitors and the ev-
idence for the pro-survival effects of PHD inhibition and HIF
stabilization, it is not likely that hepatotoxicity is a common
side effect of this class of compounds [60].
In cases of chronic liver disease, cirrhosis and HCC in par-
ticular, inhibition of HIFmay prove to be an effective treatment.
In fact, targetingHIFs is being explored to treat HCC (examples
are listed in Table 1). A HIF-1α antisense oligonucleotide,
EZN2968, has undergone phase I clinical trial in advanced
malignancies. It reduced tumor size without improving clinical
efficacy. This HIF-1α antisense antagonist (under the name
RO7070179) is now undergoing a phase 1b trial in HCC pa-
tients who have failed at least one line of systemic therapy
[168]. A fusion protein containing Gal4 and the C-terminal
41 residues of HIF-1α transactivation domain (TAD-C) is re-
ported to block the interaction of HIF-1α with its co-activator
p300/CBP. In xenograft models, this fusion protein attenuates
expression of HIF-1α target genes and reduces tumor growth
[167]. Moreover, because of the involvement of HIFs in devel-
oping resistance to chemotherapy in HCC [173–178], HIF in-
hibitors can be given in combination with current therapies. For
example, it has been shown that resistance to sorafenib can be
overcome by EF24, which induces HIF-1α degradation [179].
In vitro and in vivo studies reveal that knock-down of HIF-2α
with shRNA enhances the efficacy of sorafenib. [173, 178]
Another study shows that treatment of antisense HIF-1α
synergizes with doxorubicin in suppressing tumor
growth and angiogenesis [180]. Overall, preclinical stud-
ies strongly suggest HIF inhibition as a strategy to treat
chronic liver disease, HCC in particular. However, cau-
tions need to be taken in clinical studies. For example,
it may be important to discontinue HIF inhibitor thera-
pies in patients who are undergoing liver surgery for
HCC, as HIF inhibitors have the potential to exacerbate
IR injury and inhibit liver regeneration.
Concluding remarks
HIF stabilization has been reported in animal models and clin-
ical samples of various liver diseases. The functional conse-
quences of HIF stabilization in liver diseases are beginning to
be elucidated. Current evidence supports a hepato-protective
function of HIFs in acute liver damage. In this case, the HIF
transcriptional activities cause protection of cells, promotion of
angiogenesis, and reprogramming of cellular energy metabo-
lism. However, the same functions of HIFs result in a patho-
logical role in hepatic lipid accumulation, fibrogenesis, and
tumor progression during chronic liver diseases. These findings
indicate that HIF activation is desirable in acute liver injury, but
HIF inhibition can prevent and ameliorate chronic liver disease.
The dichotomous role of HIFs indicates that the clinical effects
of HIF modifiers may be time-sensitive and disease-dependent.
For example, in HCC patients undergoing resection or liver
transplantation, temporarily halting the use of HIF inhibitors
but instead activating HIFs may be beneficial. The same strat-
egy may be considered in liver cirrhosis patients suffering from
an episode of acute-on-chronic liver injury.
With the emerging appreciation of the involvement of HIFs
in various liver diseases, a challenge for basic research is to
elucidate the underlying molecular mechanisms. It is impor-
tant to uncover the transcriptional targets and signaling path-
ways that mediate the functions of HIFs in experimental
models. Aside from hepatocytes, multiple cell types in the
liver contribute to disease development. Therefore, it is also
critical to investigate the protective or pathological role of
cell-specific HIFs in various liver diseases. The knowledge
gained from these studies will unravel the complex involve-
ment of HIFs in liver disease and help the development of
therapeutic strategies to modulate HIFs. HIF modifiers are
actively being developed and evaluated clinically in treating
ischemia and cancer. Although some of these compounds are
undergoing clinical trials for liver transplantation and HCC,
translational research endeavor should be further emphasized
in the near future.
Acknowledgments This work was supported by U01AA021723 and
R21AA022387 (to C.J.), R01DK104713 and R01DK50189 (to S.P.C.),
and R01DK097075, R01HL092188, R01HL098294, P01HL114457,
and R01HL119837 (to H.K.E.). The authors thank Shelley Eltzschig for
her help in the preparation of the figures.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
622 J Mol Med (2016) 94:613–627
References
1. Fitzmaurice C, Dicker D, Pain A et al (2015) The global burden of
cancer 2013. JAMA Oncol 1:505–527
2. Ohh M, Park CW, Ivan M et al (2000) Ubiquitination of hypoxia-
inducible factor requires direct binding to the beta-domain of the
von Hippel-Lindau protein. Nat Cell Biol 2:423–427
3. Maxwell PH, Wiesener MS, Chang GW et al (1999) The tumour
suppressor protein VHL targets hypoxia-inducible factors for
oxygen-dependent proteolysis. Nature 399:271–275
4. Lando D, Peet DJ, Gorman JJ et al (2002) FIH-1 is an asparaginyl
hydroxylase enzyme that regulates the transcriptional activity of
hypoxia-inducible factor. Genes Dev 16:1466–1471
5. Bangoura G, Yang LY, Huang GW,WangW (2004) Expression of
HIF-2alpha/EPAS1 in hepatocellular carcinoma. World J
Gastroenterol 10:525–530
6. Corpechot C, Barbu V, Wendum D et al (2002) Hypoxia-induced
VEGF and collagen I expressions are associated with angiogenesis
and fibrogenesis in experimental cirrhosis. Hepatology 35:1010–
1021
7. Hu JL, Liu LP (2015) Yang SL et al. Hepatitis B virus induces
hypoxia-inducible factor-2alpha expression through hepatitis B
virus X protein. Oncol Rep
8. Li S, Yao D, Wang L et al (2011) Expression characteristics of
hypoxia-inducible factor-1alpha and its clinical values in diagno-
sis and prognosis of hepatocellular carcinoma. Hepat Mon 11:
821–828
9. Liu LP, HuBG, Ye C et al (2014) HBxmutants differentially affect
the activation of hypoxia-inducible factor-1alpha in hepatocellular
carcinoma. Br J Cancer 110:1066–1073
10. Novo E, Povero D, Busletta C et al (2012) The biphasic nature of
hypoxia-induced directional migration of activated human hepatic
stellate cells. J Pathol 226:588–597
11. Jungermann K, Kietzmann T (2000) Oxygen: modulator of meta-
bolic zonation and disease of the liver. Hepatology 31:255–260
12. NasimuzzamanM, Waris G, Mikolon D, Stupack DG, Siddiqui A
(2007) Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha
and stimulates the synthesis of vascular endothelial growth factor.
J Virol 81:10249–10257
13. Qu A, Taylor M, Xue X et al (2011) Hypoxia-inducible transcrip-
tion factor 2alpha promotes steatohepatitis through augmenting
lipid accumulation, inflammation, and fibrosis. Hepatology 54:
472–483
14. Wilson GK, Brimacombe CL, Rowe IA et al (2012) A dual role
for hypoxia inducible factor-1alpha in the hepatitis C virus
lifecycle and hepatoma migration. J Hepatol 56:803–809
15. Campbell EL, Bruyninckx WJ, Kelly CJ et al (2014)
Transmigrating neutrophils shape the mucosal microenvironment
through localized oxygen depletion to influence resolution of in-
flammation. Immunity 40:66–77
16. Peyssonnaux C, Cejudo-Martin P, Doedens A et al (2007) Cutting
edge: essential role of hypoxia inducible factor-1alpha in develop-
ment of lipopolysaccharide-induced sepsis. J Immunol 178:7516–
7519
17. Frede S, Stockmann C, Freitag P, Fandrey J (2006) Bacterial
lipopolysaccharide induces HIF-1 activation in human mono-
cytes via p44/42 MAPK and NF-kappaB. Biochem J 396:
517–527
18. Blouin CC, Page EL, Soucy GM, Richard DE (2004) Hypoxic
gene activation by lipopolysaccharide in macrophages: implica-
tion of hypoxia-inducible factor 1alpha. Blood 103:1124–1130
19. Tannahill GM, Curtis AM, Adamik J et al (2013) Succinate is an
inflammatory signal that induces IL-1beta through HIF-1alpha.
Nature 496:238–242
20. Guzy RD, Hoyos B, Robin E et al (2005) Mitochondrial complex
III is required for hypoxia-induced ROS production and cellular
oxygen sensing. Cell Metab 1:401–408
21. Cramer T, Yamanishi Y, Clausen BE et al (2003) HIF-1alpha is
essential for myeloid cell-mediated inflammation. Cell 112:645–
657
22. Ohta A, SitkovskyM (2001) Role of G-protein-coupled adenosine
receptors in downregulation of inflammation and protection from
tissue damage. Nature 414:916–920
23. Aherne CM, Saeedi B, Collins CB et al (2015) Epithelial-specific
A2B adenosine receptor signaling protects the colonic epithelial
barrier during acute colitis. Mucosal Immunol 8:699
24. Clambey ET, McNamee EN, Westrich JA et al (2012) Hypoxia-
inducible factor-1 alpha-dependent induction of FoxP3 drives reg-
ulatory T-cell abundance and function during inflammatory hyp-
oxia of the mucosa. Proc Natl Acad Sci U S A 109:E2784–E2793
25. Colgan SP, Eltzschig HK (2012) Adenosine and hypoxia-
inducible factor signaling in intestinal injury and recovery. Annu
Rev Physiol 74:153–175
26. Eltzschig HK, Eckle T (2011) Ischemia and reperfusion—from
mechanism to translation. Nat Med 17:1391–1401
27. Aherne CM, Kewley EM, Eltzschig HK (1808) The resurgence of
A2B adenosine receptor signaling. Biochim Biophys Acta 2011:
1329–1339
28. Eltzschig HK, Bonney SK, Eckle T (2013) Attenuating myocar-
dial ischemia by targeting A2B adenosine receptors. Trends Mol
Med 19:345–354
29. Howard TK, Klintmalm GB, Cofer JB et al (1990) The influence
of preservation injury on rejection in the hepatic transplant recip-
ient. Transplantation 49:103–107
30. Chen Y, Xie X (2012) Tacrolimus attenuates myocardium damage
to the total hepatic ischemia-reperfusion via regulation of the mi-
tochondrial function. J Surg Res 172:e47–e54
31. Serracino-Inglott F, Habib NA, Mathie RT (2001) Hepatic
ischemia-reperfusion injury. Am J Surg 181:160–166
32. Stahl JE, Kreke JE, Malek FA, Schaefer AJ, Vacanti J (2008)
Consequences of cold-ischemia time on primary nonfunction
and patient and graft survival in liver transplantation: a meta-anal-
ysis. PLoS One 3:e2468
33. Hong JC, Yersiz H, Kositamongkol P et al (2011) Liver transplan-
tation using organ donation after cardiac death: a clinical predic-
tive index for graft failure-free survival. Arch Surg 146:1017–
1023
34. Ben MI, Mouchel Y, Pajaud J et al (2012) Pretreatment with
mangafodipir improves liver graft tolerance to ischemia/
reperfusion injury in rat. PLoS One 7:e50235
35. Yang YY, Lee PC, HuangYTet al (2014) Involvement of the HIF-
1alpha and Wnt/beta-catenin pathways in the protective effects of
losartan on fatty liver graft with ischaemia/reperfusion injury. Clin
Sci (Lond) 126:163–174
36. Zhong Z, Ramshesh VK, Rehman H et al (2008) Activation of the
oxygen-sensing signal cascade prevents mitochondrial injury after
mouse liver ischemia-reperfusion. Am J Physiol Gastrointest
Liver Physiol 295:G823–G832
37. Xu Z, Chen X, Peng C et al (2012) Hypoxia-inducible factor-
1alpha suppressed hepatocellular carcinoma cell apoptosis
through influencing on Omi/HtrA2 expression and its releasing
from the mitochondrion. Oncol Res 20:213–220
38. Yoo W, Noh KH, Ahn JH et al (2014) HIF-1alpha expression as a
protective strategy of HepG2 cells against fatty acid-induced tox-
icity. J Cell Biochem 115:1147–1158
39. Cummins EP, Berra E, Comerford KM et al (2006) Prolyl
hydroxylase-1 negatively regulates IkappaB kinase-beta, giving
insight into hypoxia-induced NFkappaB activity. Proc Natl Acad
Sci U S A 103:18154–18159
J Mol Med (2016) 94:613–627 623
40. Tambuwala MM, Cummins EP, Lenihan CR et al (2010) Loss of
prolyl hydroxylase-1 protects against colitis through reduced epi-
thelial cell apoptosis and increased barrier function.
Gastroenterology 139:2093–2101
41. SchneiderM, VanGK, Fraisl P et al (2010) Loss or silencing of the
PHD1 prolyl hydroxylase protects livers of mice against ischemia/
reperfusion injury. Gastroenterology 138:1143–1154
42. Mollenhauer M, Kiss J, Dudda J et al (2012) Deficiency of the
oxygen sensor PHD1 augments liver regeneration after partial
hepatectomy. Langenbecks Arch Surg 397:1313–1322
43. Idzko M, Ferrari D, Eltzschig HK (2014) Nucleotide signalling
during inflammation. Nature 509:310–317
44. IdzkoM, Ferrari D, Riegel AK, Eltzschig HK (2014) Extracellular
nucleotide and nucleoside signaling in vascular and blood disease.
Blood 124:1029–1037
45. Hart ML, Gorzolla IC, Schittenhelm J, Robson SC, Eltzschig HK
(2010) SP1-dependent induction of CD39 facilitates hepatic ische-
mic preconditioning. J Immunol 184:4017–4024
46. Hart ML, Henn M, Kohler D et al (2008) Role of extracellular
nucleotide phosphohydrolysis in intestinal ischemia-reperfusion
injury. FASEB J 22:2784–2797
47. Hart ML, Much C, Gorzolla IC et al (2008) Extracellular adeno-
sine production by ecto-5'-nucleotidase protects during murine
hepatic ischemic preconditioning. Gastroenterology 135:1739–
1750
48. Eltzschig HK, Carmeliet P (2011) Hypoxia and inflammation. N
Engl J Med 364:656–665
49. Eltzschig HK, Sitkovsky MV, Robson SC (2012) Purinergic sig-
naling during inflammation. N Engl J Med 367:2322–2333
50. Chouker A, Ohta A, Martignoni A et al (2012) In vivo hypoxic
preconditioning protects from warm liver ischemia-reperfusion
injury through the adenosine A2B receptor. Transplantation 94:
894–902
51. Eltzschig HK, Ibla JC, Furuta GTet al (2003) Coordinated adenine
nucleotide phosphohydrolysis and nucleoside signaling in
posthypoxic endothelium: role of ectonucleotidases and adenosine
A2B receptors. J Exp Med 198:783–796
52. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP
(2006) HIF-dependent induction of adenosine A2B receptor in
hypoxia. FASEB J 20:2242–2250
53. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J
(2006) Adenosine A2A receptor activation reduces hepatic ische-
mia reperfusion injury by inhibiting CD1d-dependent NKT cell
activation. J Exp Med 203:2639–2648
54. Ahmad A, Ahmad S, Glover L et al (2009) Adenosine A2A re-
ceptor is a unique angiogenic target of HIF-2alpha in pulmonary
endothelial cells. Proc Natl Acad Sci U S A 106:10684–10689
55. Eltzschig HK, Abdulla P, Hoffman E et al (2005) HIF-1-
dependent repression of equilibrative nucleoside transporter
(ENT) in hypoxia. J Exp Med 202:1493–1505
56. Morote-Garcia JC, Kohler D, Roth JM et al (2013) Repression of
the equilibrative nucleoside transporters dampens inflammatory
lung injury. Am J Respir Cell Mol Biol 49:296–305
57. Guo JY, Yang T, Sun XG et al (2011) Ischemic postconditioning
attenuates liver warm ischemia-reperfusion injury through Akt-
eNOS-NO-HIF pathway. J Biomed Sci 18:79
58. Plock J, Frese S, KeoghA et al (2007) Activation of non-ischemic,
hypoxia-inducible signalling pathways up-regulate cytoprotective
genes in the murine liver. J Hepatol 47:538–545
59. Amador A, Grande L, Marti J et al (2007) Ischemic pre-
conditioning in deceased donor liver transplantation: a prospec-
tive randomized clinical trial. Am J Transplant 7:2180–2189
60. Eltzschig HK, Bratton DL, Colgan SP (2014) Targeting hypoxia
signalling for the treatment of ischaemic and inflammatory dis-
eases. Nat Rev Drug Discov 13:852–869
61. Bedogni G, Miglioli L, Masutti F et al (2005) Prevalence of and
risk factors for nonalcoholic fatty liver disease: the Dionysos nu-
trition and liver study. Hepatology 42:44–52
62. Nonomura A, Mizukami Y, Unoura M et al (1992)
Clinicopathologic study of alcohol-like liver disease in non-
alcoholics; non-alcoholic steatohepatitis and fibrosis.
Gastroenterol Jpn 27:521–528
63. Omagari K, Kadokawa Y,Masuda J et al (2002) Fatty liver in non-
alcoholic non-overweight Japanese adults: incidence and clinical
characteristics. J Gastroenterol Hepatol 17:1098–1105
64. McCullough AJ (2011) Epidemiology of the metabolic syndrome
in the USA. J Dig Dis 12:333–340
65. Torres DM, Harrison SA (2008) Diagnosis and therapy of nonal-
coholic steatohepatitis. Gastroenterology 134:1682–1698
66. Szczepaniak LS, Nurenberg P, Leonard D et al (2005) Magnetic
resonance spectroscopy to measure hepatic triglyceride content:
prevalence of hepatic steatosis in the general population. Am J
Physiol Endocrinol Metab 288:E462–E468
67. Argo CK, Caldwell SH (2009) Epidemiology and natural history
of non-alcoholic steatohepatitis. Clin Liver Dis 13:511–531
68. Hui JM, Kench JG, Chitturi S et al (2003) Long-term outcomes of
cirrhosis in nonalcoholic steatohepatitis compared with hepatitis
C. Hepatology 38:420–427
69. Adams LA, Lymp JF, St SJ et al (2005) The natural history of
nonalcoholic fatty liver disease: a population-based cohort study.
Gastroenterology 129:113–121
70. Nasrin N, Wu X, Fortier E et al (2010) SIRT4 regulates fatty acid
oxidation and mitochondrial gene expression in liver and muscle
cells. J Biol Chem 285:31995–32002
71. Kondo K, Sugioka T, Tsukada K et al (2010) Fenofibrate, a per-
oxisome proliferator-activated receptor alpha agonist, improves
hepatic microcirculatory patency and oxygen availability in a
high-fat-diet-induced fatty liver in mice. Adv Exp Med Biol 662:
77–82
72. Henly DC, Berry MN (1993) Effect of palmitate concentration on
the relative contributions of the beta-oxidation pathway and citric
acid cycle to total O2 consumption of isolated rat hepatocytes.
Biochim Biophys Acta 1175:269–276
73. Piguet AC, Stroka D, Zimmermann A, Dufour JF (2010) Hypoxia
aggravates non-alcoholic steatohepatitis in mice lacking hepato-
cellular PTEN. Clin Sci (Lond) 118:401–410
74. Gordon GB, Barcza MA, Bush ME (1977) Lipid accumulation of
hypoxic tissue culture cells. Am J Pathol 88:663–678
75. Parathath S, Mick SL, Feig JE et al (2011) Hypoxia is present in
murine atherosclerotic plaques and has multiple adverse effects on
macrophage lipid metabolism. Circ Res 109:1141–1152
76. Furuta E, Pai SK, Zhan R et al (2008) Fatty acid synthase gene is
up-regulated by hypoxia via activation ofAkt and sterol regulatory
element binding protein-1. Cancer Res 68:1003–1011
77. Minamishima YA, Moslehi J, Padera RF et al (2009) A feedback
loop involving the Phd3 prolyl hydroxylase tunes the mammalian
hypoxic response in vivo. Mol Cell Biol 29:5729–5741
78. Rankin EB, Rha J, Selak MA et al (2009) Hypoxia-inducible
factor 2 regulates hepatic lipid metabolism. Mol Cell Biol 29:
4527–4538
79. Kim WY, Safran M, Buckley MR et al (2006) Failure to prolyl
hydroxylate hypoxia-inducible factor alpha phenocopies VHL in-
activation in vivo. EMBO J 25:4650–4662
80. Suzuki T, Shinjo S, Arai T, Kanai M, Goda N (2014) Hypoxia and
fatty liver. World J Gastroenterol 20:15087–15097
81. Mandayam S, Jamal MM, Morgan TR (2004) Epidemiology of
alcoholic liver disease. Semin Liver Dis 24:217–232
82. O’Shea RS, Dasarathy S, McCullough AJ (2010) Alcoholic liver
disease. Hepatology 51:307–328
83. Gao B, Bataller R (2011) Alcoholic liver disease: pathogenesis
and new therapeutic targets. Gastroenterology 141:1572–1585
624 J Mol Med (2016) 94:613–627
84. Raynard B, Balian A, Fallik D et al (2002) Risk factors of fibrosis
in alcohol-induced liver disease. Hepatology 35:635–638
85. Naveau S, Giraud V, Borotto E et al (1997) Excess weight risk
factor for alcoholic liver disease. Hepatology 25:108–111
86. Siu L, Foont J, Wands JR (2009) Hepatitis C virus and alcohol.
Semin Liver Dis 29:188–199
87. Yuki T, Thurman RG (1980) The swift increase in alcohol metab-
olism. Time course for the increase in hepatic oxygen uptake and
the involvement of glycolysis. Biochem J 186:119–126
88. Israel Y, Videla L, Macdonald A, Bernstein J (1973) Metabolic
alterations produced in the liver by chronic ethanol administration.
Comparison between the effects produced by ethanol and by thy-
roid hormones. Biochem J 134:523–529
89. French SW (2004) The role of hypoxia in the pathogenesis of
alcoholic liver disease. Hepatol Res 29:69–74
90. Arteel GE, Raleigh JA, Bradford BU, Thurman RG (1996) Acute
alcohol produces hypoxia directly in rat liver tissue in vivo: role of
Kupffer cells. Am J Physiol 271:G494–G500
91. Arteel GE, Iimuro Y, Yin M, Raleigh JA, Thurman RG (1997)
Chronic enteral ethanol treatment causes hypoxia in rat liver tissue
in vivo. Hepatology 25:920–926
92. Nishiyama Y, Goda N, KanaiM et al (2012) HIF-1alpha induction
suppresses excessive lipid accumulation in alcoholic fatty liver in
mice. J Hepatol 56:441–447
93. Nath B, Levin I, Csak T et al (2011) Hepatocyte-specific hypoxia-
inducible factor-1alpha is a determinant of lipid accumulation and
liver injury in alcohol-induced steatosis in mice. Hepatology 53:
1526–1537
94. Li L, Chen SH, Zhang Y et al (2006) Is the hypoxia-inducible
factor-1 alpha mRNA expression activated by ethanol-induced
injury, the mechanism underlying alcoholic liver disease?
Hepatobiliary Pancreat Dis Int 5:560–563
95. Alcolado R, Arthur MJ, Iredale JP (1997) Pathogenesis of liver
fibrosis. Clin Sci (Lond) 92:103–112
96. Stewart SF, Day CP (2003) The management of alcoholic liver
disease. JHepatol 38(Suppl 1):S2–13
97. Coulon S, Heindryckx F, Geerts A et al (2011) Angiogenesis in
chronic liver disease and its complications. Liver Int 31:146–162
98. Cabibbo G, Maida M, Genco C, Antonucci M, Camma C (2012)
Causes of and prevention strategies for hepatocellular carcinoma.
Semin Oncol 39:374–383
99. Hashimoto E, Yatsuji S, Tobari M et al (2009) Hepatocellular
carcinoma in patients with nonalcoholic steatohepatitis. J
Gastroenterol 44(Suppl 19):89–95
100. Vanhaecke T, Foriers A, Geerts A et al (2001) Pyruvate-induced
long-term maintenance of glutathione s-transferase in rat hepato-
cyte cultures. Altern Lab Anim 29:335–346
101. Onori P,Morini S, Franchitto A et al (2000) Hepatic microvascular
features in experimental cirrhosis: a structural and morphometrical
study in CCl4-treated rats. J Hepatol 33:555–563
102. Moon JO, Welch TP, Gonzalez FJ, Copple BL (2009) Reduced
liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice.
Am.J Physiol Gastrointest. Liver Physiol 296:G582–G592
103. Novo E, Cannito S, Zamara E et al (2007) Proangiogenic cyto-
kines as hypoxia-dependent factors stimulating migration of hu-
man hepatic stellate cells. Am J Pathol 170:1942–1953
104. Roychowdhury S, Chiang DJ, McMullen MR, Nagy LE (2014)
Moderate, chronic ethanol feeding exacerbates carbon-
tetrachloride-induced hepatic fibrosis via hepatocyte-specific hyp-
oxia inducible factor 1alpha. Pharmacol Res Perspect 2:e00061
105. Copple BL, Kaska S,Wentling C (2012) Hypoxia-inducible factor
activation in myeloid cells contributes to the development of liver
fibrosis in cholestatic mice. J Pharmacol Exp Ther 341:307–316
106. Chan ES, Montesinos MC, Fernandez P et al (2006) Adenosine
A(2A) receptors play a role in the pathogenesis of hepatic cirrho-
sis. Br J Pharmacol 148:1144–1155
107. Chiang DJ, Roychowdhury S, Bush K et al (2013) Adenosine 2A
receptor antagonist prevented and reversed liver fibrosis in a
mouse model of ethanol-exacerbated liver fibrosis. PLoS ONE
8:e69114
108. Mustafa SJ, Nadeem A, FanM et al (2007) Effect of a specific and
selective A(2B) adenosine receptor antagonist on adenosine ago-
nist AMP and allergen-induced airway responsiveness and cellular
influx in a mouse model of asthma. J Pharmacol Exp Ther 320:
1246–1251
109. Ceradini DJ, Gurtner GC (2005) Homing to hypoxia: HIF-1 as a
mediator of progenitor cell recruitment to injured tissue. Trends
Cardiovasc Med 15:57–63
110. Higgins DF, Kimura K, Bernhardt WM et al (2007) Hypoxia pro-
motes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-
mesenchymal transition. J Clin Invest 117:3810–3820
111. Sun S, Ning X, Zhang Y et al (2009) Hypoxia-inducible factor-
1alpha induces Twist expression in tubular epithelial cells subject-
ed to hypoxia, leading to epithelial-to-mesenchymal transition.
Kidney Int 75:1278–1287
112. Wilson GK, Tennant DA, McKeating JA (2014) Hypoxia induc-
ible factors in liver disease and hepatocellular carcinoma: current
understanding and future directions. J Hepatol 61:1397–1406
113. El-Serag HB (2012) Epidemiology of viral hepatitis and hepato-
cellular carcinoma. Gastroenterology 142:1264–1273
114. Arbuthnot P, Capovilla A, KewM (2000) Putative role of hepatitis
B virus X protein in hepatocarcinogenesis: effects on apoptosis,
DNA repair, mitogen-activated protein kinase and JAK/STAT
pathways. J Gastroenterol Hepatol 15:357–368
115. Ripoli M, D’Aprile A, Quarato G et al (2010) Hepatitis C virus-
linkedmitochondrial dysfunction promotes hypoxia-inducible fac-
tor 1 alpha-mediated glycolytic adaptation. J Virol 84:647–660
116. Liu Y, Sui J, Zhai L et al (2014) Genetic polymorphisms in
hypoxia-inducible factor-1a gene and its association with HBV-
related hepatocellular carcinoma in a Chinese population. Med
Oncol 31:200
117. Moon EJ, Jeong CH, Jeong JW et al (2004) Hepatitis B virus X
protein induces angiogenesis by stabilizing hypoxia-inducible fac-
tor-1alpha. FASEB J 18:382–384
118. Yoo YG, Cho S, Park S, Lee MO (2004) The carboxy-terminus of
the hepatitis B virus X protein is necessary and sufficient for the
activation of hypoxia-inducible factor-1alpha. FEBS Lett 577:
121–126
119. Yoo YG, Na TY, Seo HWet al (2008) Hepatitis B virus X protein
induces the expression of MTA1 and HDAC1, which enhances
hypoxia signaling in hepatocellular carcinoma cells. Oncogene 27:
3405–3413
120. Yoo YG, Oh SH, Park ES et al (2003) Hepatitis B virus X protein
enhances transcriptional activity of hypoxia-inducible factor-1al-
pha through activation of mitogen-activated protein kinase path-
way. J Biol Chem 278:39076–39084
121. Vassilaki N, Kalliampakou KI, Kotta-Loizou I et al (2013) Low
oxygen tension enhances hepatitis C virus replication. J Virol 87:
2935–2948
122. Mee CJ, Harris HJ, Farquhar MJ et al (2009) Polarization restricts
hepatitis C virus entry into HepG2 hepatoma cells. J Virol 83:
6211–6221
123. Mee CJ, Farquhar MJ, Harris HJ et al (2010) Hepatitis C virus
infection reduces hepatocellular polarity in a vascular endothelial
growth factor-dependent manner. Gastroenterology 138:1134–
1142
124. Burnstock G, Boeynaems JM (2014) Purinergic signalling and
immune cells. Purinergic Signal 10:529–564
125. SitkovskyMV, Hatfield S, Abbott R et al (2014) Hostile, hypoxia-
A2-adenosinergic tumor biology as the next barrier to overcome
for tumor immunologists. Cancer Immunol Res 2:598–605
J Mol Med (2016) 94:613–627 625
126. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics.
CA Cancer J Clin 61:69–90
127. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: ep-
idemiology and molecular carcinogenesis. Gastroenterology 132:
2557–2576
128. ParkinDM (2001) Global cancer statistics in the year 2000. Lancet
Oncol 2:533–543
129. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson
SD (2008) Hepatocellular carcinoma: epidemiology, risk factors
and pathogenesis. World J Gastroenterol 14:4300–4308
130. Aravalli RN, Steer CJ, Cressman EN (2008) Molecular mecha-
nisms of hepatocellular carcinoma. Hepatology 48:2047–2063
131. Cabrera R, Nelson DR (2010) Review article: the management of
hepatocellular carcinoma. Aliment Pharmacol Ther 31:461–476
132. Liu Y, Liu Y, Yan X et al (2014) HIFs enhance the migratory and
neoplastic capacities of hepatocellular carcinoma cells by promot-
ing EMT. Tumour Biol 35:8103–8114
133. Bangoura G, Liu ZS, Qian Q et al (2007) Prognostic significance
of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma.
World J Gastroenterol 13:3176–3182
134. Simon F, BockhornM, Praha C et al (2010) Deregulation of HIF1-
alpha and hypoxia-regulated pathways in hepatocellular carcino-
ma and corresponding non-malignant liver tissue—influence of a
modulated host stroma on the prognosis of HCC. Langenbecks
Arch Surg 395:395–405
135. Xiang ZL, Zeng ZC, Fan J et al (2012) The expression of HIF-
1alpha in primary hepatocellular carcinoma and its correlation
with radiotherapy response and clinical outcome. Mol Biol Rep
39:2021–2029
136. Yang SL, Liu LP, Jiang JX et al (2014) The correlation of expres-
sion levels of HIF-1alpha and HIF-2alpha in hepatocellular carci-
noma with capsular invasion, portal vein tumor thrombi and pa-
tients’ clinical outcome. Jpn J Clin Oncol 44:159–167
137. Zheng SS, Chen XH, Yin X, Zhang BH (2013) Prognostic signif-
icance of HIF-1alpha expression in hepatocellular carcinoma: a
meta-analysis. PLoS One 8:e65753
138. Guo X, Li D, Chen Yet al (2015) SNP rs2057482 in HIF1A gene
predicts clinical outcome of aggressive hepatocellular carcinoma
patients after surgery. Sci Rep 5:11846
139. Hsiao PC, ChenMK, Su SC et al (2010) Hypoxia inducible factor-
1alpha gene polymorphism G1790A and its interaction with to-
bacco and alcohol consumptions increase susceptibility to hepato-
cellular carcinoma. J Surg Oncol 102:163–169
140. Wu XZ, Xie GR, Chen D (2007) Hypoxia and hepatocellular
carcinoma: the therapeutic target for hepatocellular carcinoma. J
Gastroenterol Hepatol 22:1178–1182
141. Xie H, Song J, Liu K et al (2008) The expression of hypoxia-
inducible factor-1alpha in hepatitis B virus-related hepatocellular
carcinoma: correlation with patients’ prognosis and hepatitis B
virus X protein. Dig Dis Sci 53:3225–3233
142. Ke Q, Costa M (2006) Hypoxia-inducible factor-1 (HIF-1). Mol
Pharmacol 70:1469–1480
143. Luo D, Wang Z, Wu J, Jiang C, Wu J (2014) The role of hypoxia
inducible factor-1 in hepatocellular carcinoma. Biomed Res Int
2014:409272
144. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev
Cancer 3:721–732
145. Xia L, Mo P, Huang W et al (2012) The TNF-alpha/ROS/HIF-1-
induced upregulation of FoxMI expression promotes HCC prolif-
eration and resistance to apoptosis. Carcinogenesis 33:2250–2259
146. Putzer BM (2007) E2F1 death pathways as targets for cancer
therapy. J Cell Mol Med 11:239–251
147. Sun HX, Xu Y, Yang XR et al (2013) Hypoxia inducible factor 2
alpha inhibits hepatocellular carcinoma growth through the tran-
scription factor dimerization partner 3/ E2F transcription factor 1-
dependent apoptotic pathway. Hepatology 57:1088–1097
148. Carmeliet P, Dor Y, Herbert JM et al (1998) Role of HIF-1alpha in
hypoxia-mediated apoptosis, cell proliferation and tumour angio-
genesis. Nature 394:485–490
149. Kim JW, Dang CV (2006) Cancer’s molecular sweet tooth and the
Warburg effect. Cancer Res 66:8927–8930
150. Semenza GL, Roth PH, Fang HM, Wang GL (1994)
Transcriptional regulation of genes encoding glycolytic enzymes
by hypoxia-inducible factor 1. J Biol Chem 269:23757–23763
151. Semenza GL (2007) HIF-1 mediates the Warburg effect in clear
cell renal carcinoma. J Bioenerg Biomembr 39:231–234
152. Seagroves TN, Ryan HE, Lu H et al (2001) Transcription factor
HIF-1 is a necessary mediator of the pasteur effect in mammalian
cells. Mol Cell Biol 21:3436–3444
153. Josko J, Gwozdz B, Jedrzejowska-Szypulka H, Hendryk S (2000)
Vascular endothelial growth factor (VEGF) and its effect on an-
giogenesis. Med Sci Monit 6:1047–1052
154. Kim JW (2010) Hypoxia-inducible factor 1, hepatocellular carci-
noma and angiogenesis. Korean J Hepatol 16:278–279
155. Rey S, Semenza GL (2010) Hypoxia-inducible factor-1-
dependent mechanisms of vascularization and vascular remodel-
ling. Cardiovasc Res 86:236–242
156. Imai T, Horiuchi A, Wang C et al (2003) Hypoxia attenuates the
expression of E-cadherin via up-regulation of SNAIL in ovarian
carcinoma cells. Am J Pathol 163:1437–1447
157. Krishnamachary B, Zagzag D, Nagasawa H et al (2006) Hypoxia-
inducible factor-1-dependent repression of E-cadherin in von
Hippel-Lindau tumor suppressor-null renal cell carcinoma medi-
ated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66:2725–
2731
158. Yang MH, Wu MZ, Chiou SH et al (2008) Direct regulation of
TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10:
295–305
159. Zhang L, Huang G, Li X et al (2013) Hypoxia induces epithelial-
mesenchymal transition via activation of SNAI1 by hypoxia-
inducible factor -1alpha in hepatocellular carcinoma. BMC
Cancer 13:108
160. Yang MH, Chen CL, Chau GY et al (2009) Comprehensive anal-
ysis of the independent effect of twist and snail in promoting
metastasis of hepatocellular carcinoma. Hepatology 50:1464–
1474
161. Okazaki I, Inagaki Y (2012) Novel strategies for hepatocellular
carcinoma based on MMPs science. Anticancer Agents Med
Chem 12:753–763
162. Sato H, Kida Y, Mai M et al (1992) Expression of genes encoding
type IV collagen-degrading metalloproteinases and tissue inhibi-
tors of metalloproteinases in various human tumor cells.
Oncogene 7:77–83
163. Ding JY, Kreipke CW, Schafer P et al (2009) Synapse loss regu-
lated by matrix metalloproteinases in traumatic brain injury is
associated with hypoxia inducible factor-1alpha expression.
Brain Res 1268:125–134
164. Erdozain OJ, Pegrum S, Winrow VR, Horrocks M, Stevens CR
(2011) Hypoxia in abdominal aortic aneurysm supports a role for
HIF-1alpha and Ets-1 as drivers of matrix metalloproteinase up-
regulation in human aortic smooth muscle cells. J Vasc Res 48:
163–170
165. Fujiwara S, Nakagawa K, Harada H et al (2007) Silencing
hypoxia-inducible factor-1alpha inhibits cell migration and inva-
sion under hypoxic environment in malignant gliomas. Int J Oncol
30:793–802
166. Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ (2003) Effect of
ascorbate on the activity of hypoxia-inducible factor in cancer
cells. Cancer Res 63:1764–1768
167. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM (2000)
Suppression of tumor growth through disruption of hypoxia-
inducible transcription. Nat Med 6:1335–1340
626 J Mol Med (2016) 94:613–627
168. Lin D, Wu J (2015) Hypoxia inducible factor in hepatocellular
carcinoma: a therapeutic target. World J Gastroenterol 21:
12171–12178
169. Rapisarda A, Uranchimeg B, Sordet O et al (2004) Topoisomerase
I-mediated inhibition of hypoxia-inducible factor 1: mechanism
and therapeutic implications. Cancer Res 64:1475–1482
170. Abe Y, Uchinami H, Kudoh K et al (2012) Liver epithelial cells
proliferate under hypoxia and protect the liver from ischemic injury
via expression of HIF-1 alpha target genes. Surgery 152:869–878
171. Maeno H, Ono T, Dhar DK et al (2005) Expression of hypoxia
inducible factor-1alpha during liver regeneration induced by par-
tial hepatectomy in rats. Liver Int 25:1002–1009
172. Tajima T, Goda N, Fujiki N et al (2009) HIF-1alpha is necessary to
support gluconeogenesis during liver regeneration. Biochem
Biophys Res Commun 387:789–794
173. Liu F, Dong X, Lv H et al (2015) Targeting hypoxia-inducible
factor-2alpha enhances sorafenib antitumor activity via beta-ca-
tenin/C-Myc-dependent pathways in hepatocellular carcinoma.
Oncol Lett 10:778–784
174. Meijer TW, Kaanders JH, Span PN, Bussink J (2012) Targeting
hypoxia, HIF-1, and tumor glucose metabolism to improve radio-
therapy efficacy. Clin Cancer Res 18:5585–5594
175. Schwartz DL, Bankson J, Bidaut L et al (2011) HIF-1-dependent
stromal adaptation to ischemia mediates in vivo tumor radiation
resistance. Mol Cancer Res 9:259–270
176. Wu L, Fu Z, Zhou S et al (2014) HIF-1alpha and HIF-2alpha:
siblings in promoting angiogenesis of residual hepatocellular
carcinoma after high-intensity focused ultrasound ablation. PLoS
One 9:e88913
177. Yamada S, Utsunomiya T, Morine Y et al (2014) Expressions of
hypoxia-inducible factor-1 and epithelial cell adhesion molecule
are linked with aggressive local recurrence of hepatocellular car-
cinoma after radiofrequency ablation therapy. Ann Surg Oncol
21(Suppl 3):S436–S442
178. Zhao D, Zhai B, He C et al (2014) Upregulation of HIF-2alpha
induced by sorafenib contributes to the resistance by activating the
TGF-alpha/EGFR pathway in hepatocellular carcinoma cells. Cell
Signal 26:1030–1039
179. Liang Y, Zheng T, Song R et al (2013) Hypoxia-mediated sorafe-
nib resistance can be overcome by EF24 through Von Hippel-
Lindau tumor suppressor-dependent HIF-1alpha inhibition in he-
patocellular carcinoma. Hepatology 57:1847–1857
180. Liu F, Wang P, Jiang X et al (2008) Antisense hypoxia-inducible
factor 1alpha gene therapy enhances the therapeutic efficacy of
doxorubicin to combat hepatocellular carcinoma. Cancer Sci 99:
2055–2061
181. Eckle T, Brodsky K, Bonney M et al (2013) HIF1A reduces acute
lung injury by optimizing carbohydrate metabolism in the alveolar
epithelium. PLoS Biol 11:e1001665
182. Hartmann H, Eltzschig HK, Wurz H et al (2008) Hypoxia-
independent activation of HIF-1 by enterobacteriaceae and their
siderophores. Gastroenterology 134:756–767
J Mol Med (2016) 94:613–627 627
